finance.yahoo.com ·
veracyte inc q1 2026 earnings 001835867
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedVeracyte's earnings beat and raised guidance signal strong commercial traction in genomic testing for cancer. Decipher's growth in high-risk prostate cancer and upcoming product launches (Prosigna, TruMRD) expand addressable market. No direct commodity or supply chain impact; company-specific revenue/margin improvement. Sector: diagnostic testing within healthcare.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Veracyte Q1 2026 adjusted EBITDA margin 30.8% vs 25% target.
- Decipher volume +24% YoY, high-risk categories nearly +30%.
- 2026 revenue guidance raised to $582M-$592M.
- Afirma expected high single-digit to low double-digit growth; Decipher ~20% growth.
- Upcoming launches: Prosigna LDT and TruMRD.
Sustained volume growth and upcoming product launches support mid-term revenue expansion for Veracyte's tests.
Sign in to see all sector verdicts, full thesis and counter-argument debate.